Table 2.
Characteristics of the 60 compensated cirrhosis cohort divided into 28 stable control patients followed longitudinally in this paper, and those non-returner patients excluded as they either failed to return for repeat assessments or developed a clinical outcome. Also shown is the 10 healthy volunteer group followed longitudinally
| Compensated cirrhosis | Healthy volunteers | ||
|---|---|---|---|
| Stable returners | Non-returners | ||
| N | 28 | 32 | 10 |
| Gender | 17 male (61%) | 18 male (56%) | 6 male (60%) |
| Age (years) | 59 (8) | 59 (13) | 63 (4) |
| Aetiology | 29% NALFD/18% ALD/25% HCV/28% other | 40% NAFLD/37% ALD/15% HCV/7% other | N/A |
| BMI (kg/m2) | 27.5 (5.6) | 28.5 (4.9) | 26 (3.0) |
| MELD | 7.5 (1.6) | 6.9 (1.8) | N/A |
| UKELD | 43.1 (2.9) | 43.5 (2.3) | N/A |
| APRI | 0.71 (0.61) | 0.71 (1.2) | N/A |
| FIB4 | 2.5 (1.8) | 2.9 (1.9) | N/A |
| ELF score | 10.2 (1.2) | 11.5 (1.9) | 8.9 (0.8) |
| Fibroscan® LSM (kPa) | 18 (17) | 23 (21) | N/A |
Numbers in parentheses correspond to the standard deviation in measures unless stated otherwise
NAFLD Non-alcoholic fatty liver disease, ALD Alcoholic liver disease, HCV Hepatitis C virus, BMI Body mass index, MELD Model for end-stage liver disease, UKELD United Kingdom model for end-stage liver disease, APRI Aspartate aminotransferase to platelet ratio index, FIB4 Fibrosis-4, ELF Enhanced liver fibrosis, LSM Liver stiffness measure